We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to... FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc. Show more
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on...
HOUSTON, June 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on...
HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development...
| Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.86 | -37.6315789474 | 7.6 | 7.77 | 3.99 | 154452 | 6.20949513 | CS |
| 4 | -6.44 | -57.602862254 | 11.18 | 13.59 | 3.99 | 307225 | 9.36494878 | CS |
| 12 | -6.09 | -56.2326869806 | 10.83 | 13.59 | 3.99 | 141156 | 9.70996467 | CS |
| 26 | -25.26 | -84.2 | 30 | 55 | 3.99 | 128593 | 10.91383143 | CS |
| 52 | -25.26 | -84.2 | 30 | 55 | 3.99 | 128593 | 10.91383143 | CS |
| 156 | -25.26 | -84.2 | 30 | 55 | 3.99 | 128593 | 10.91383143 | CS |
| 260 | -25.26 | -84.2 | 30 | 55 | 3.99 | 128593 | 10.91383143 | CS |
Invest-in-America
2 weeks ago
tw0122
2 weeks ago
enthalpy
4 months ago
Monksdream
4 months ago
Invest-in-America
4 months ago
GhosTraderX
4 months ago
TheFinalCD
4 months ago
Monksdream
5 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
